Barclays PLC Increases Holdings in Aspen Aerogels, Inc. (NYSE:ASPN)

Barclays PLC boosted its holdings in Aspen Aerogels, Inc. (NYSE:ASPN - Free Report) by 333.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 92,302 shares of the construction company's stock after buying an additional 71,024 shares during the quarter. Barclays PLC owned approximately 0.11% of Aspen Aerogels worth $2,557,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the business. Point72 Hong Kong Ltd acquired a new stake in Aspen Aerogels during the second quarter worth approximately $84,000. nVerses Capital LLC acquired a new stake in Aspen Aerogels during the 2nd quarter worth $95,000. Quent Capital LLC purchased a new stake in Aspen Aerogels in the third quarter valued at $118,000. Point72 DIFC Ltd purchased a new stake in Aspen Aerogels in the second quarter valued at $121,000. Finally, Public Employees Retirement Association of Colorado acquired a new position in Aspen Aerogels in the second quarter valued at $145,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

Aspen Aerogels Stock Performance

Shares of NYSE:ASPN traded down $0.15 during midday trading on Wednesday, hitting $11.90. The stock had a trading volume of 865,365 shares, compared to its average volume of 1,630,059. Aspen Aerogels, Inc. has a 1 year low of $10.75 and a 1 year high of $33.15. The company has a current ratio of 2.93, a quick ratio of 2.48 and a debt-to-equity ratio of 0.27. The stock has a 50 day moving average price of $15.89 and a two-hundred day moving average price of $22.02. The company has a market capitalization of $976.36 million, a PE ratio of 1,191.19 and a beta of 2.12.

Insider Activity at Aspen Aerogels

In other Aspen Aerogels news, CEO Donald R. Young sold 63,355 shares of the business's stock in a transaction on Monday, September 30th. The shares were sold at an average price of $30.03, for a total transaction of $1,902,550.65. Following the sale, the chief executive officer now directly owns 483,640 shares in the company, valued at approximately $14,523,709.20. The trade was a 11.58 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 4.30% of the stock is owned by insiders.

Analyst Ratings Changes

Several analysts have recently weighed in on ASPN shares. Barclays reduced their target price on Aspen Aerogels from $27.00 to $25.00 and set an "overweight" rating for the company in a report on Tuesday, November 12th. StockNews.com upgraded Aspen Aerogels to a "sell" rating in a research note on Wednesday, November 13th. Piper Sandler lowered their target price on shares of Aspen Aerogels from $36.00 to $33.00 and set an "overweight" rating on the stock in a research report on Tuesday, October 22nd. Roth Mkm cut their target price on shares of Aspen Aerogels from $36.00 to $31.00 and set a "buy" rating on the stock in a report on Friday, November 8th. Finally, HC Wainwright reiterated a "buy" rating and set a $30.00 price target on shares of Aspen Aerogels in a research note on Wednesday, October 16th. One analyst has rated the stock with a sell rating, nine have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $28.70.

About Aspen Aerogels

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.